Pharmaceuticals
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.
This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 28.
IBM to Drop Co-Pay for Some Doctor Visits
Email this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In an unusual bid to cut health-care costs, IBM plans to stop requiring $20 co-payments by employees when they visit primary-care physicians.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Aurobindo gets South African regulator's nod to market drugsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Drug firm, Aurobindo Pharma today said it has received approval from the South African regulator to manufacture and market two drugs in that country.
Source: The Economic Times Healthcare and Biotech News - October 29, 2009 Category: Pharmaceuticals Source Type: news
First Phase III clinical trial of Roche's weekly taspoglutide meets primary end-point of change in HbA1cEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD), showed that the trial met its primary endpoint of change in HbA1c. Superiority versus exenatide was demonstrated.
Source: Roche Investor Update - October 29, 2009 Category: Pharmaceuticals Source Type: organizations
First Phase III clinical trial of Roche`s weekly taspoglutide meets primary end-point of change in HbA1cEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD), showed that the trial met its primary endpoint of change in HbA1c. Superiority versus exenatide was demonstrated.
Source: Roche Investor Update - October 29, 2009 Category: Pharmaceuticals Source Type: organizations
Malvern Instruments And Kaiser Optical Systems Collaborate To Develop An Advanced Range Of Raman MicroscopesEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Materials characterization company Malvern Instruments (Malvern, Worcs, UK) and Kaiser Optical Systems (Ann Arbor, MI, USA), a leading supplier of Raman analyzers and components for spectroscopy, announce a development collaboration that will enhance the product portfolios of both companies.
Source: Pharmaceutical Online News - October 29, 2009 Category: Pharmaceuticals Source Type: news
FrieslandCampina Domo Name Change Process Aims To Ensure A Seamless Transition For American CustomersEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
As FrieslandCampina Domo implements its entity change process, the operating company's primary goal is to ensure a smooth and seamless transition for its customers.
Source: Pharmaceutical Online News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in IllinoisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Abbott.com - October 29, 2009 Category: Pharmaceuticals Source Type: organizations
SP Industries' Freeze Dryers Get GreenerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
SP Industries Inc. has announced that its VirTis Genesis 25 and 35 XL Freeze Drying Systems, now featuring proprietary auto-cascade refrigeration technology, can achieve low freeze drying temperatures while reducing operational energy consumption by 30 to 40% compared to two compressor cascade systems.
Source: Pharmaceutical Online News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Bantam™ Magnet And Magna-Bar From Eriez® Provide A Solution For Automation And Separation ApplicationsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Eriez® offers two permanent, non-electric bar magnets to meet many automation, separation and holding requirements. "These powerful and economical magnets are ideal for a wide variety of applications," said John Mackowski, Product Manager.
Source: Pharmaceutical Online News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Public-Option Liberals Hold SwayEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Senate Majority Leader Harry Reid's decision to include a public option in the health bill may have been influenced by some Democrats who warned Reid they would oppose a bill that didn't include it.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Business Groups Fight Health BillEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Employers are blasting the Senate's plan to create a public health-insurance program after being caught by surprise when the public option resurfaced.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Heat Device Treats AsthmaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
An FDA panel recommended that the agency approve a first-of-kind device to treat severe asthma patients.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
IBM to Drop Co-Pay for Primary-Care VisitsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
In an unusual bid to cut health-care costs, IBM plans to stop requiring $20 co-payments by employees when they visit primary-care physicians.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Public-Option Liberals Hold SwayEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Senate Majority Leader Harry Reid's decision to include a public option in the health bill may have been influenced by some Democrats who warned Reid they would oppose a bill that didn't include it.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Business Groups Fight Health BillEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Employers are blasting the Senate's plan to create a public health-insurance program after being caught by surprise when the public option resurfaced.
Source: WSJ.com: Health - October 29, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Pfizer keen to buy Wockhardt's biotech businessEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The American company has just completed the $68-billion acquisition of biotech major Wyeth, which is a new drug developer.
Source: The Economic Times Healthcare and Biotech News - October 29, 2009 Category: Pharmaceuticals Source Type: news
DENTSPLY International Inc. Reports Third Quarter 2009 Sales and EarningsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
YORK, Pa., Oct. 28, 2009 (GLOBE NEWSWIRE) -- DENTSPLY International Inc. (Nasdaq:XRAY) today announced sales and earnings for the three months ended September 30, 2009. Net sales in the third quarter of 2009 increased 0.2% to $531.0 million compared to $530.0 million reported for the third quarter of 2008. Net sales, without precious metal content, increased 1.1% to $493.6 million in the third quarter of 2009. The change in net sales, excluding precious metal content, was driven by an increase of 2.5% in constant currency including acquisitions, partially offset by currency translation, which reduced sales by 1.4% in the period.
Source: Medical News (via PRIMEZONE) - October 29, 2009 Category: Pharmaceuticals Source Type: news
Abbott Completes Visiogen AcquisitionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Abbott (NYSE: ABT) has completed its acquisition of privately held eye care company Visiogen, expanding the company's vision care business with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients.
Source: World Pharma News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Forest Laboratories, Inc. and Gedeon Richter Announce Results from a Phase IIb Study of CariprazineEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.
Source: World Pharma News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Merck and Schering-Plough Receive Approvals From U.S. Federal Trade Commission, Swiss Competition Commission and Canadian Competition Bureau for MergerEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Source: Merck.com - Corporate News - October 29, 2009 Category: Pharmaceuticals Source Type: news
Medicare, Medicaid Fraud TargetedEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Lawmakers said the government needs to step up efforts to fight Medicare and Medicaid fraud to generate more savings to help pay for a health-care overhaul.
Source: WSJ.com: Health - October 28, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
FDA Issues Guidance for Derma Sciences' Exclusive Wound Dressing With pDADMACEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Paves the Way for the Company to Develop a Full Line of BIOGUARD(TM) Dressings Based on Patented Antimicrobial / Barrier Technology
PRINCETON, N.J., Oct. 28 (HSMN NewsFeed) -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI ), a specialty medical devic... Devices, Wound Care, FDADerma Sciences, BIOGUARD
Source: HSMN NewsFeed - October 28, 2009 Category: Pharmaceuticals Source Type: news
Medicare to Pay More To Doctors for AvastinEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Medicare plans to increase reimbursements to eye doctors using Genentech's's Avastin in patients, reversing a controversial decision that had cut the payments more than 80%.
Source: WSJ.com: Health - October 28, 2009 Category: Pharmaceuticals Tags: PAID Source Type: news
HeartWare to Report 2009 Third Quarter and Nine Month Financial ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
FRAMINGHAM, Mass. and SYDNEY, Australia, Oct. 28, 2009 (GLOBE NEWSWIRE) -- HeartWare International, Inc. (Nasdaq:HTWR) (ASX:HIN) will release financial results for the third quarter and nine months ended September 30, 2009 after the U.S. markets close on Wednesday, November 4, 2009.
Source: Medical News (via PRIMEZONE) - October 28, 2009 Category: Pharmaceuticals Source Type: news
House Compromises on Public OptionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
House Democratic leaders are likely to include a compromise version of a public insurance option in sweeping health-care-overhaul legislation that could be unveiled as early as Thursday.
Source: WSJ.com: Health - October 28, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
Difficult-to-Treat Patient Populations Respond Positively to Hepatitis C TreatmentEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Presentation: Sunday, November 1, 2009, 4:45 pm Eastern Time
in Boston, MA
ALEXANDRIA, Va., and BOSTON, Oct. 28 /PRNewswire/ -- The final
results of the PROVE3 study will be presented at this year's annual
meeting of the American Association for the...
Source: Drugs.com - Clinical Trials - October 28, 2009 Category: Pharmaceuticals Source Type: clinical trials
Forest Laboratories, Inc. and Gedeon Richter Announce Positive Results from a Phase IIb Study of Cariprazine for the Treatment of SchizophreniaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
NEW YORK & BUDAPEST, Hungary--(BUSINESS WIRE)--Oct 28, 2009
- Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc
today announced positive top-line results from a Phase IIb clinical
trial of the novel, investigational antipsychotic agent...
Source: Drugs.com - Clinical Trials - October 28, 2009 Category: Pharmaceuticals Source Type: clinical trials
HealthCentral partners with online video startup to create largest health video networkEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
5min and HealthCentral Announce New Online Health Video
Network
Reaches Largest Health Audience Online; 5min as Exclusive
Distribution Platform Enables Health Sites to Instantly Monetize
Relevant Video Content
ARLINGTON, VA AND NEW YORK (OCTOBER 28,...
Source: Drugs.com - Pharma News - October 28, 2009 Category: Pharmaceuticals Source Type: news
SCYNEXIS to Present HCV Data on Novel Cyclophilin Inhibitor SCY-635 at AASLD Annual MeetingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Oct 28, 2009 -
Drug discovery company SCYNEXIS, Inc. today announced that
supportive data from a preclinical study of the Company's lead
product candidate for hepatitis C (HCV), SCY-635, will be...
Source: Drugs.com - Clinical Trials - October 28, 2009 Category: Pharmaceuticals Source Type: clinical trials
GSK steps along desired path of evolutionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The group's traditional core market of prescription medicines in developed countries may fall to just a quarter of total sales according to Andrew Witty, chief executive of GSK
Source: FT.com - Drugs and Healthcare - October 28, 2009 Category: Pharmaceuticals Source Type: news
Updated European guidelines highlight benefits of Rasilez, the only approved direct renin inhibitor, in treating high blood pressureEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
• Updated European Society of Hypertension (ESH) guidelines
recognize that Rasilez® monotherapy is effective at lowering
blood pressure in a single daily dose1
• Rasilez is also effective in combination with either a
diuretic, a calcium...
Source: Drugs.com - Clinical Trials - October 28, 2009 Category: Pharmaceuticals Source Type: clinical trials
Study demonstrates effectiveness of once-daily dose of Asacol for ulcerative colitisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Largest prospective controlled trial in UC meets primary
endpoint of non-inferiority for maintaining remission in UC
patients
TORONTO, October 28, 2009 – Results from the largest
prospective controlled ulcerative colitis (UC) trial conducted...
Source: Drugs.com - Clinical Trials - October 28, 2009 Category: Pharmaceuticals Source Type: clinical trials
House Compromises on Public OptionEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
House Democratic leaders are likely to include a compromise version of a public insurance option in sweeping health-care-overhaul legislation that could be unveiled as early as Thursday.
Source: WSJ.com: Health - October 28, 2009 Category: Pharmaceuticals Tags: FREE Source Type: news
LeMaitre Vascular Q3 2009 Record Sales $13.3mm (up 11%), Op. Profit $1.3mmEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
BURLINGTON, Mass., Oct. 28, 2009 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices and implants, today announced Q3 2009 financial results, posting record quarterly sales of $13.3 million, record operating income of $1.3 million and increased cash and marketable securities of $2.9 million. The Company also increased its 2009 top- and bottom-line guidance while doubling its stock repurchase program from $1 million to $2 million.
Source: Medical News (via PRIMEZONE) - October 28, 2009 Category: Pharmaceuticals Source Type: news
Cerner Reports Third Quarter 2009 ResultsEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
KANSAS CITY, Mo., Oct. 28, 2009 (GLOBE NEWSWIRE) -- Cerner Corp. (Nasdaq:CERN) today announced results for the 2009 third quarter that ended October 3, 2009, delivering record levels of bookings, and strong cash flow and earnings.
Source: Medical News (via PRIMEZONE) - October 28, 2009 Category: Pharmaceuticals Source Type: news
PSS World Medical Reports Results for Fiscal Year 2010 Second QuarterEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Second Quarter Highlights:
Source: Medical News (via PRIMEZONE) - October 28, 2009 Category: Pharmaceuticals Source Type: news
Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary CirrhosisEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
NEW YORK, Oct. 27 /PRNewswire/ -- Intercept Pharmaceuticals,
Inc., today announced positive results from a 165 patient, placebo
controlled, double-blind Phase II clinical trial of INT-747 in
patients with primary biliary cirrhosis (PBC). The...
Source: Drugs.com - Clinical Trials - October 28, 2009 Category: Pharmaceuticals Source Type: clinical trials
New Data Supports Pharmacoeconomic Benefits of CepleneEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
TARRYTOWN, N.Y.--(BUSINESS WIRE)--Oct 26, 2009 - Regulatory
News:
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT)
announces the release of new findings demonstrating the
pharmacoeconomic benefits of Ceplene®...
Source: Drugs.com - Clinical Trials - October 28, 2009 Category: Pharmaceuticals Source Type: clinical trials
Nurse Staffing For SafetyEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
We have heard a lot about safe staffing and mandated staffing ratios, but is it a good idea to legislate nurse staffing? Medscape Nurses
Source: Medscape Business of Medicine Headlines - October 28, 2009 Category: Pharmaceuticals Tags: Nursing Source Type: info
Weak Pound Boosts Glaxo NetEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The U.K. drug maker reported strong profit and sales growth in the third quarter, helped by a weaker pound and acquisitions, and said the pace of its H1N1 vaccine production is improving.
Source: WSJ.com: Health - October 28, 2009 Category: Pharmaceuticals Tags: PAID Source Type: news
Cancer Beats AstraZenecaEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
Company pulls application for a promising experimental drug.
Source: Forbes.com Healthcare News - October 28, 2009 Category: Pharmaceuticals Source Type: news
Use of Antipsychotic Medications by Children and Adolescents Associated With Significant Weight GainEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CHICAGO, Oct. 27, 2009—Many pediatric and adolescent
patients who received second-generation antipsychotic medications
experienced significant weight gain, along with varied adverse
effects on cholesterol and triglyceride levels and other...
Source: Drugs.com - Pharma News - October 28, 2009 Category: Pharmaceuticals Source Type: news
Weak Pound Boosts Glaxo NetEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
The U.K. drug maker reported strong profit and sales growth in the third quarter, helped by a weaker pound and acquisitions, and said the pace of its H1N1 vaccine production is improving.
Source: WSJ.com: Health - October 28, 2009 Category: Pharmaceuticals Tags: PAID Source Type: news
Elekta Demonstrates Continued Leadership in Image Guidance at 2009 ASTRO Annual MeetingEmail this article to a colleague.
Save this article to My Clippings.
Discuss or comment on this article.
CHICAGO, Oct. 28 (HSMN NewsFeed) -- At the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), November 1 - 5 in Chicago, Illinois, Elekta will showcase new tools that demonstrate the IGRT-pioneer's continued leadership in oncolog... Devices, OncologyElekta, Elekta Infinity, VMAT, MOSAIQ, Gamma Knife, radiotherapy
Source: HSMN NewsFeed - October 28, 2009 Category: Pharmaceuticals Source Type: news
